<DOC>
	<DOCNO>NCT01738867</DOCNO>
	<brief_summary>A total least 48 healthy subject history social drinking recruit single-centre , randomize , double-blind , cross-over study . Subjects genetically stratify result equal number A118G 'AA ' homozygote ( n=24 ) A118G ' G ' carrier ( n=24 ) . Subjects participate three treatment period randomize receive follow 5 day : Treatment A : Placebo , Treatment B : Naltrexone ( NTX ) 50 mg daily ( 25 mg daily first two day ) Treatment C : GSK1521498 10 mg daily . A washout period least 14 day treatment . Subjects return follow-up visit 7-10 day final treatment session washout period complete . Subjects attend clinical research unit day 1 , 2 , 3 , 4 5 monitor safety tolerability drug . Subjects attend clinical unit day 4 5 two day assessment , use series pharmacodynamic measurement know sensitive effect GSK1521498 and/or NTX : Functional brain response alcohol food cue ; plasma cortisol ; hedonic consummatory eat behavior ; subjective response ethanol challenge ; experimental pain threshold ; cognitive test attention bias towards alcohol food cue .</brief_summary>
	<brief_title>To Evaluate Influence A118G Polymorphism mu Opioid Receptor Gene ( OPRM1 ) Effects GSK1521498 Naltrexone Physiological Behavioural Markers Brain Function Healthy Social Drinkers</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Caucasian male female 18 65 year age inclusive , time signing informed consent BMI normal range great , equal 22 kilogram ( kg ) per meter square ( m^2 ) , otherwise healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Self report alcohol drinking frequency 3 drink men ( 2 drink woman ) least two day per week , average score 6 high AlcoholUseDisordersIdentification Test ( AUDIT ) . Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) &lt; 2xUpper Limit Normal ( ULN ) ; alkaline phosphatase bilirubin &lt; =1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . A female subject eligible participate childbearing potential abstinent agree use one accepted contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 14 day receive last dose study medication . Male subject female partner childbearing potential must agree use one acceptable contraception method . This criterion must follow time first dose study medication 14 day receive last dose study medication . Capable give write informed consent , include compliance requirement restriction list consent form , capacity participate aspect assessment . Psychiatric illness substance abuse : Current past history Diagnostic Statistical Manual Mental Disorders ( DSMIV ) alcohol substance dependence abuse , include treatmentseeking behaviour , determine Investigator Miniinternational neuropsychiatric interview ( MINI ) . Self administer Beck Depression Inventory II scale total score great 13 suicide question score great zero screening . Current past chronic history neurological disorder . Current past history Axis 1 psychiatric disorder include eat disorder anorexia nervosa , bulimia nervosa binge eat disorder , include treatment seek behaviour use MINI . Subject , investigator/designee 's judgement , pose significant suicide risk . Evidence serious suicide risk may include history suicidal behaviour and/or evidence suicidal ideation questionnaire e.g . type 4 5 CSSRS last 5 year . Concomitant drug use : Positive urine screen amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine screen . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 14 day prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Miscellaneous : Special dietary requirement ( e.g . vegetarian , vegan , religious , food intolerantdiets ) , accommodate experimental design important participant offer test meal snack choice inunit assessment people special dietary requirement exclude . Subjects unsuitable cannulation . Any contraindication logistical complication anticipate relation magnetic resonance imaging ( MRI ) scan endpoint assessment , judgment Principal Investigator , include : presence cardiac pacemaker electronic device ferromagnetic metal foreign body assess standard preMRI questionnaire , claustrophobia , inability lie still back approximately hour . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 3 month , 5 halflives twice duration biological effect investigational product ( whichever longer ) . QTcB QTcF &gt; 450 millisecond ( msec ) . Note initial QTc value prolong , ECG repeat two time ( 5 minute ECG reading ) average 3 QTc value use determine eligibility . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody HIV test result within 3 month screen . Exposure four new chemical entity within 12 month prior first dose day . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 milliliter ( mL ) within 56 day period . Pregnant lactating female . Occupational use heavy machinery . Heavy smoker i.e &gt; 15 cigarette per day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>mu opioid receptor</keyword>
	<keyword>Addiction</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>OPRM1</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>